RecruitingPhase not listedNCT07091019
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
Sponsor: Novartis Pharmaceuticals
East Setauket, NY · Syracuse, NY · +15 more sites